Interleukin-2 for Refractory Chronic Spontaneous Urticaria

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

the Second Xiangya Hospital of Central South University, Changsha, Hunan

Phase

Safety & dosing / Large-scale testing

Sponsor

Second Xiangya Hospital of Central South University

Collaborators

Xiangya Hospital of Central South University, Third Affiliated Hospital, Sun Yat-Sen University

Enrollment target

~124 participants

Started

March 2025

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 74 Years

Last updated April 2025